Evaluation of Serological Tests To Identify *Trypanosoma cruzi* Infection in Humans and Determine Cross-Reactivity with *Trypanosoma rangeli* and *Leishmania* spp.  

Zuleima C. Caballero, Octavio E. Sousa, Waldelania P. Marques, Amadeo Saez-Alquezar, and Eufrosina S. Umezawa

Instituto de Medicina Tropical de São Paulo (IMT) and Departamento de Medicina Preventiva da Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Enéas de Carvalho Aguiar 470, CEP 05403-000, and Panel Assessoria & Controle de Qualidade, São Paulo, Brazil, and Faculdade de Medicina, Universidade de Panamá, Panamá City, Panamá

Received 19 March 2007/Returned for modification 23 April 2007/Accepted 14 May 2007

Five commercially available enzyme-linked immunosorbent assays (ELISAs), one in-house ELISA, and two hemagglutination assays were evaluated to determine their diagnostic accuracy for Chagas’ disease in two studies. In study I, ELISA kits showed 100% sensitivity, but specificities ranged from 82.84% to 100% when leishmaniasis cases were included and from 95.57% to 100% when leishmaniasis cases were excluded. Kits using recombinant antigens or synthetic peptides are more specific than those using crude extracts from *Trypanosoma cruzi* epimastigote forms. Kits evaluated in Panama, in study II, showed 75% to 100% sensitivity and 97.12% to 100% specificity. These data were obtained by using a Western blot assay with *T. cruzi* trypomastigote excreted-secreted antigens as a reference test to confirm *T. cruzi* infection.

Chagas’ disease is caused by the protozoan *Trypanosoma cruzi*, which is transmitted to humans by blood-sucking triatomine bugs, by blood transfusion, through the placenta, or by ingestion of contaminated food. It is estimated that 9 to 12 million people on the Latin American continent are infected with *T. cruzi*. The prevalence of Chagas’ disease among blood donors from different countries in South America differs within each country and locality (8, 22). However, in recent decades, several million persons have emigrated to developed countries, and this may lead to an increase in the prevalence of the infection in such countries (3, 8, 22). Indeed, infection with *T. cruzi* transmitted by blood transfusion or organ transplantation has recently been described in the United States (1, 5, 8, 9, 19).

Serological diagnosis of Chagas’ disease is frequently based on tests such as enzyme-linked immunosorbayss (EIAs), indirect immunofluorescence assays, and indirect hemagglutination assays (IHAs), which usually employ *T. cruzi* epimastigote forms as the antigen. Provided that good-quality kits are selected and correct laboratory practices followed, good sensitivity can be achieved with any of the tests. Sensitivities on the order of 95 to 99% can be obtained, and these can be increased to 100% by using more than one test (8, 10, 15). The use of recombinant antigens and/or synthetic peptides has been proposed (17, 21) to improve specificity and sensitivity, which is essential if false-positive or false-negative results are to be avoided.

Several reports show that results can be inconclusive or doubtful depending on the commercial diagnostic assay used for blood screening (5, 6, 7). The definition of inconclusive results differs with the commercial kit used, since reactions that are not clearly positive or negative are taken as inconclusive. Currently available kits are very effective at detecting blood donors presenting with high anti-*T. cruzi* antibody titers, but the results are often questionable when the kits are used for donors with low titers (7, 18). For the latter donors, it is not uncommon for a sample to be negative by one test when subjected to two or three tests (8). Some of these samples are known to be from genuine Chagas’ disease patients, because they are confirmed by molecular biology methods (PCR) (7); other researchers have reported evidence that people infected with *T. cruzi* can have negative serology (16, 23).

Another factor that needs to be taken into consideration when one is using serological tests for Chagas’ disease is cross-reactivity. Cross-reactivity between sera of patients infected with *T. cruzi* and sera of patients infected with *Leishmania* spp. in the serodiagnosis of Chagas’ disease is well documented (2, 10). In some areas of endemicity in Central America and Brazil, where *T. cruzi* and the nonpathogenic protozoan *Trypanosoma rangeli* can be found infecting the same vectors and vertebrate hosts (12, 14), cross-reactivity has been the subject of discussion.

The aim of our study, which was divided into two separate studies (studies 1 and 2), was to compare the sensitivities and specificities of nine Chagas’ disease assays for detection of anti-*T. cruzi* immunoglobulin G: six enzyme-linked immunosorbent assays (ELISAs), two IHAs, and one Western blot assay. Of these tests, the following seven are commercially available: three ELISAs manufactured with *T. cruzi* epimastigote antigens (ELISA Chagas III [BIOSChile–Ingenieria Genética SA, Santiago, Chile], ELISAcruzi [bioMérieux Brasil SA], and Chagatek ELISA [Laboratório Lemos SRL, Buenos Aires, Argentina; distributed by bioMérieux Argentina]), two
ELISAs prepared with recombinant *T. cruzi* antigens (Chagatest ELISA recombinant, version 3.0 [Chagatest Rec v3.0; Wiener Diagnostics Laboratories, Rosario, Argentina], and Pathozyme Chagas [Omega Diagnostics Ltd., Scotland, United Kingdom]), and two IHAs (HEMACruzi [bioMérieux Brasil] and Imuno-HAI [Wama Diagnóstica, São Paulo, Brazil]). The following two tests were prepared at the Instituto de Medicina Tropical, São Paulo, Brazil (IMT): ELISA-IMT, which was prepared with whole extracts of *T. cruzi* Y strain epimastigotes, and a Western blot assay, prepared with *T. cruzi* trypomastigote excreted-secreted antigens (TESA blot), as previously described (20). The TESA blot was used as a reference test (20, 21, 23). All commercial kits were used according to the manufacturers’ instructions, and the test results were analyzed in accordance with the technical information provided for each assay. The cutoffs were calculated as described in the respective sections of each manual. For ELISA-IMT, the cutoff was calculated as the mean optical density (OD) at 492 nm of the true-negative sera plus 3 standard deviations. The individual results were calculated as the ratio of the OD to the cutoff (see Fig. 1). A sample was considered positive if the ratio was equal to or greater than 1.0 and negative if the ratio was equal to or smaller than 0.99. Seropositivity rates for anti-*T. cruzi* antibodies in different tests, and their confidence intervals [CIs], were calculated using the mid-P 95% confidence interval (95% CI) using Epi Info (version 6.0) software (see Table 2). Samples that yielded discrepant results were tested at least twice on different days.

The guidelines of the Standards for Reporting of Diagnostic Accuracy were applied in this study.

In study 1, all ELISAs and the TESA blot had a sensitivity of 100% (95% CI, 94.5 to 100%) when evaluated with 53 samples collected from Brazilian blood donors with *T. cruzi* infection (18 to 60 years old; 60% male, 40% female) who had previ-

### Table 1. Numbers and percentages of positive cases obtained by six ELISAs for Chagas’ disease diagnosis using the TESA blot as a reference test

<table>
<thead>
<tr>
<th>Status of patients</th>
<th>No. of cases</th>
<th>TESA blot (IMT)</th>
<th>ELISA-IMT&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Chagas III (BIOSChile)&lt;sup&gt;b&lt;/sup&gt;</th>
<th>ELISAChag (bioMérieux Brasil SA)&lt;sup&gt;c&lt;/sup&gt;</th>
<th>Chagatest (bioMérieux Brasil SA)&lt;sup&gt;d&lt;/sup&gt;</th>
<th>Chagatest Rec v3.0 (Wiener)&lt;sup&gt;e&lt;/sup&gt;</th>
<th>Pathozyme Chagas (Omega)&lt;sup&gt;f&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chagas’ disease patients</td>
<td>187</td>
<td>53 (100)</td>
<td>53 (100)</td>
<td>53 (100)</td>
<td>53 (100)</td>
<td>53 (100)</td>
<td>53 (100)</td>
<td>53 (100)</td>
</tr>
<tr>
<td>Subjects without Chagas’ disease</td>
<td>134</td>
<td>45</td>
<td>0</td>
<td>2 (92.31)</td>
<td>1 (92.31)</td>
<td>11 (84.60)</td>
<td>0</td>
<td>13 (81.25)</td>
</tr>
<tr>
<td>Healthy</td>
<td>100 (94.5–100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VL&lt;sup&gt;a&lt;/sup&gt;</td>
<td>100 (97.8–100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CL&lt;sup&gt;a&lt;/sup&gt;</td>
<td>100 (97.4–100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T. rangeli</td>
<td>100 (82.9–100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other infections</td>
<td>100 (97.2–100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TESA blot positive</td>
<td>16</td>
<td>16 (100)</td>
<td>16 (100)</td>
<td>15 (93.75)</td>
<td>16 (100)</td>
<td>13 (10.83)</td>
<td>12 (10.00)</td>
<td></td>
</tr>
<tr>
<td>TESA blot negative</td>
<td>104</td>
<td>104</td>
<td>2 (1.92)</td>
<td>1 (0.96)</td>
<td>3 (2.88)</td>
<td>2 (1.92)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Study 2 (Panamanians)</td>
<td>120</td>
<td>120</td>
<td>16 (15.00)</td>
<td>16 (13.33)</td>
<td>15 (10.83)</td>
<td>12 (10.00)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Test prepared at the IMT.  
<sup>b</sup> ELISA prepared with *T. cruzi* epimastigote antigens.  
<sup>c</sup> ELISA prepared with *T. cruzi* recombinant proteins.  
<sup>d</sup> VL, visceral leishmaniasis.  
<sup>e</sup> CL, cutaneous leishmaniasis.

### Table 2. Sensitivities and specificities of seven assays to detect Trypanosoma cruzi antibodies

<table>
<thead>
<tr>
<th>Test</th>
<th>Study 1 (n = 113)</th>
<th>Study 2 (n = 120)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sensitivity&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Specificity&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>(n = 53)</td>
<td>(n = 113)</td>
</tr>
<tr>
<td>TESA blot (IMT)</td>
<td>100 (94.5–100)</td>
<td>100 (97.8–100)</td>
</tr>
<tr>
<td>ELISA-IMT&lt;sup&gt;a&lt;/sup&gt;</td>
<td>100 (94.5–100)</td>
<td>85.07 (78.3–90.4)</td>
</tr>
<tr>
<td>Chagas III (BIOSChile)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>100 (94.5–100)</td>
<td>90.30 (84.3–94.5)</td>
</tr>
<tr>
<td>ELISAChag (bioMérieux Brasil SA)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>100 (94.5–100)</td>
<td>82.84 (75.7–88.5)</td>
</tr>
<tr>
<td>Chagatest (bioMérieux Brasil SA)&lt;sup&gt;d&lt;/sup&gt;</td>
<td>100 (94.5–100)</td>
<td>87.31 (80.9–92.2)</td>
</tr>
<tr>
<td>Chagatest Rec v3.0 (Wiener)&lt;sup&gt;e&lt;/sup&gt;</td>
<td>100 (94.5–100)</td>
<td>98.08 (93.8–99.7)</td>
</tr>
<tr>
<td>Pathozyme Chagas (Omega)&lt;sup&gt;f&lt;/sup&gt;</td>
<td>100 (94.5–100)</td>
<td>75 (50.1–91.5)</td>
</tr>
</tbody>
</table>

<sup>a</sup> Both sensitivity and specificity are given as percentages, with 95% CIs in parentheses. Confidence intervals were calculated using the mid-P 95% confidence interval (95% CI) with Epi Info 6.0 software.  
<sup>b</sup> Determined with sera from non-Chagas’ disease patients.  
<sup>c</sup> ELISA prepared with *T. cruzi* epimastigote antigens.  
<sup>d</sup> ELISA prepared with *T. cruzi* recombinant proteins.
ously been found positive by at least two commercial tests. This sensitivity was obtained for ELISAs manufactured with crude epimastigote antigens as well as with recombinant *T. cruzi* proteins (Tables 1 and 2; Fig. 1, Ch). Because the bioMérieux Brasil and Wama IHAs had low sensitivities (90.56% [48/53] and 86.79% [46/53], respectively), they were excluded from subsequent analysis.

Specificity was evaluated with 134 samples collected from subjects without Chagas’ disease, including (i) 45 healthy people (20 Brazilian blood donors and 25 Panamanians living in an area of endemicity), (ii) 21 patients infected with *Leishmania* spp., (iii) 23 *T. rangeli*-infected Panamanians, and (iv) 45 patients with unrelated diseases, as defined by their respective clinical and laboratory diagnoses (5 with connective tissue diseases who were also positive for antinuclear antibodies, 5 with systemic lupus erythematosus, 5 positive for anti-streptolysin O, 5 with rheumatic fever, 5 with malaria, 5 with *Toxoplasma gondii*, 5 with *Toxocara canis*, 5 with *Schistosoma mansoni*, and 5 with *Taenia solium*) (Table 1). Patients infected with *T. rangeli* or *Leishmania* spp. were selected using epidemiological, clinical, and/or parasitological data (data not shown).

In study 1, the specificities (95% CIs) of EIAs prepared with *T. cruzi* epimastigote antigens, including results for *Leishmania* spp. cases, were as follows: for ELISA-IMT, 85.07% (78.3 to 90.4%); for Chagas III, 90.30% (84.3 to 94.5%); for ELISAcruzi, 82.84% (75.7 to 88.5%); and for Chagatest, 87.31% (80.9 to 92.2%) (Table 2; Fig. 1). A specificity of 100% (97.8 to 100%) was achieved with EIAs prepared with recombinant *T. cruzi* antigens (Chagatest Rec v3.0 and Pathozyme) (Table 2). When leishmaniasis cases (*n* = 21) were excluded, the specificities of the kits (95.57 to 100%) indicated improved diagnostic performance (Table 2). No cross-reactivity with the 23 *T. rangeli* cases was observed in the ELISAs or the TESA blot, except for the ELISA-IMT, which cross-reacted with two cases (8.69%). These two patients had low titers (Table 1; Fig. 1, Tr).
No cross-reactivity was observed with samples from T. rangeli or Leishmania sp. cases or from cases with other infections by using the TESA blot (Table 1). However, 2.24% (3/134) of the samples (1 from a healthy individual, 1 from an individual infected with Leishmania spp., and 1 from an individual infected with T. rangeli) reacted, resulting in a faint band of 170 kDa in the TESA blot; this band can be confused with the 150- to 160-kDa band that is evident with sera of T. cruzi-infected individuals (data not shown).

Individuals infected with T. rangeli appear not to produce T. cruzi- or T. rangeli-reactive antibodies; they failed to show reactivity in an ELISA prepared with T. rangeli extracts (data not shown). These results, which agree with the findings of other studies, show that human infection with T. rangeli does not cause the production of enough cross-reacting antibodies to interfere with the serodiagnosis of Chagas’ disease (13, 14). However, this does not exclude the possibility that exposure to T. rangeli may elicit a particular humoral and/or cellular immune response that confers some degree of protection against subsequent infection with T. cruzi (11).

The next step, in study 2, was to validate these assays by a retrospective study with 120 samples from individuals, aged 18 to 60 years, living in an area of endemcity in Mendoza, Panama. According to an earlier study, 2.91% and 6.80% of the children in this area are infected with T. cruzi and T. rangeli, respectively (13). In study 2, Chagas III gave positive results for 13.33% (n = 16) of the samples. ELISA-IMT, ELISA-Acruzi, and Chagatek gave a positivity rate of 15% (n = 18). Positivity rates for Chagatek Rec v3.0 and Pathozone were 10.83% (n = 13) and 10% (n = 12), respectively (Table 1). The sensitivity, calculated using the TESA blot as a reference test, was 100% (82.9 to 100.0%) for the ELISA-IMT and Chagatek tests. The same result was not observed for the other tests; Chagas III and ELISA-Acruzi had a sensitivity of 93.75% (72.8 to 99.7%), Chagatek Rec v3.0 had 81.25% (57.0 to 95.0%), and Pathozone had 75% (50.1 to 91.5%) (Table 2; Fig. 1, Study 2). In this study, the specificities (95% CIs) of tests were also variable, since cross-reactivity was observed for ELISA-IMT and Chagatek in two cases (98.08% [93.8 to 99.7%]), for Chagas III in one case (99.04% [95.4 to 100.0%]), and for ELISA-Acruzi in three cases (97.12% [92.4 to 99.3%]) (Tables 1 and 2).

In summary, our data, and those from other laboratories, indicate that commercial kits that use recombinant antigens or synthetic peptides are a more specific alternative to those that use complex crude extracts, although they sometimes have variable sensitivities (18, 21). Confirmatory tests with higher specificities have already been proposed as reference standards (3, 4, 20, 21, 23), but unfortunately none of these are commercially available.

This study was supported by grants from LIM49-FMUSP and CNPq, and was approved by the ICB Scientific Commission for Ethical Research, USP, Brazil. We are grateful to the following laboratories, which provided the commercial kits used in this study: bioMérieux Brasil, Wiener Laboratories, Abbott Laboratórios, Dade Behring, and Wama Diagnóstica.

We thank Monica de Paula Leal for invaluable technical help with the TESA blot assays.

REFERENCES


Downloaded from http://cvi.asm.org/ on October 19, 2017 by guest.

